Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTEST: ATTR-01 in Adult Participants With Select Epithelial Solid Tumours
NCT06977737Phase 2Recruiting
- Sponsor
- Accession Therapeutics
- Start
- Mar 2025
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of TROCEPT-X in solid tumor, sponsored by Accession Therapeutics. Primary endpoints: Incidence of treatment emergent adverse events at 5 years, Determination of the optimal dose of ATTR-01 at 5 years and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
TROCEPT-X
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06977737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977737.